

Global Antibody Drug Conjugates 2025

Comprehensive ADC Insights Covering:

© Technologies © Patents © Pipeline © Funding © Deals

Disclaimer

At the time of creation of this report, all information present herein was known to be true and accurate, to the best knowledge of creators. HH BioTechnologies accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without warranty, and HH BioTechnologies makes no representation of warranty of any kind as to the accuracy or completeness of any information here to contained.

ISBN 978-81-926399-0-5

© June 2025 by HH BioTechnologies Pvt. Ltd. All rights reserved.

All information contained in this publication is copyrighted in the name of HH BioTechnologies Pvt. Ltd., and no part of this publication may be reproduced, resold, redistributed, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopying, scanning, or otherwise—without prior written permission of the publisher.

Permissions may be sought directly from HH Biotechnologies' through an email at reports@omicsx.com

REPORT


GLOBAL ANTIBODY DRUG CONJUGATES 2025

DRUG DEVELOPMENT INTELLIGENCE

World's Largest Active Resource for Decision Making

Complete Insights on ADC Drug Developers

© Patents © Technologies © Pipeline © Funding © Deals



Introduction

Table of Contents

List of Antibody Drug Conjugates (ADCs) Drug Developers.....

4

6

13

Section A

□

The Rise of Antibody-Drug Conjugates

Market Momentum, Innovation Engines & the Road to 2030

31

□

Recent Advances in Antibody Drug Conjugates (ADCs) Development

Approved ADCs: Commercial Performance Overview | Market Size, Indication & Geography.

32

□

Current Global ADC Market Landscape (2025)

Approved ADCs: Commercial Performance Overview | Market Size, Indication & Geography.

34

□

Forecasting the Future: ADC Market Outlook to 2030.

Expected Market Growth & Investment Trends | Pipeline Highlights: Potential Approvals by 2030

36

□

Top 10 Pharma Companies ADC Development Strategies.

Expected Market Growth & Investment Trends | Pipeline Highlights: Potential Approvals by 2030

37

Antibody Drug Conjugates (ADC) Technology Development Landscape - 2025

39

A Conjugation Technologies – An Evolving Pillar of ADC Design

- **Engineered Reactive Cysteines / Cysteine Conjugation.** (17 Technologies) **41**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Enzymatic Conjugation.** (13 Technologies) **44**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Fc Affinity Mediated Conjugation.** (2 Technologies) **46**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Glycan Remodelling & Glycoconjugation.** (9 Technologies) **47**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Linker-Controlled Conjugation Technology.** (3 Technologies) **49**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Modification of N-/C-Terminal of Antibody.** (4 Technologies) **50**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Native Cysteine Rebridging / Disulfide Bridging.** (4 Technologies) **51**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners
- **Unnatural Amino Acids (UAA) Engineering.** (7 Technologies) **52**
Developers | Tech. Name | Conjugation Chemistry | Description | Partners

B ADCs Payload Technologies : A Strategic Overview **54**

- **Microtubule Inhibitors.** (7 Proprietary Payloads)
- **Non-Tubulin Mitotic Inhibitors.** (1 Proprietary Payloads)
- **DNA-Damaging Agents.** (5 Proprietary Payloads)
- **Topoisomerase Inhibitors.** (6 Proprietary Payloads)
- **Novel / Emerging Payload Classes.** (11 Proprietary Payloads)

C Linker Technologies -Engineering Smarter ADCs (51 Proprietary Linkers) **57**

Proprietary Linker Platform | Developed By | Key Features / Mechanism

Dual Payload ADC's in Development **62**

- **38 Companies with Dual Payload ADCs in Pipeline | Platform | Assesses**

ADC Drug Developer's Recent Patents Insights **65**

- **Drug Developer's Exclusive ADC Linked Patents Details**
(455 ADC Linked Patents Description with Patent Number and Date)

□ Antibody Drug Conjugates (ADC) Targets in Development Landscape - 2025

82

Insights on TOP 50 Emerging Targets Diversity in ADC Space

ADC Targets can be Grouped in Five Major Clusters based on their Clinical Maturity and Promise -

Cluster A □ Approved / Clinically Validated Targets :

(Includes Approved ADC's Targets / Positive Pivotal Trials)

- | | | |
|-----|---|------------|
| A.1 | Human Epidermal Growth Factor Receptor 2 (HER2) -
Insights on three approved HER2 targeting ADCs - (<i>Kadcyla, Enhertu, RC48</i>).
HER2 Targeting ADCs in Clinical & Preclinical Pipeline.
HER2 Targeting Bispecific ADCs in Clinical & Preclinical Pipeline. | 83 |
| A.2 | Trophoblast Cell Surface Antigen 2 (TROP2) -
Insights on three approved TROP2 targeting ADCs - (<i>Trodelvy, Datroway, sac-TMT</i>).
TROP2 Targeting ADCs in Clinical & Preclinical Pipeline.
TROP2 Targeting Bispecific ADCs in Clinical & Preclinical Pipeline. | 89 |
| A.3 | Nectin Cell Adhesion Molecule 4 (Nectin 4) -
Insights on approved Nectin 4 targeting ADC (<i>Padcev</i>).
Nectin 4 Targeting ADCs in Clinical & Preclinical Pipeline.
Nectin 4 Targeting Bispecific ADCs in Clinical & Preclinical Pipeline. | 94 |
| A.4 | FOLATE RECEPTOR α (FRα) -
Insights on approved FR α targeting ADC - (<i>Elahere</i>)
FR α targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 96 |
| A.5 | TISSUE FACTOR -
Insights on approved Tissue Factor targeting ADC - (<i>Tivdak</i>).
Tissue Factor ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 98 |
| A.6 | Cluster of Differentiation-22 (CD22) -
Insights on approved CD22 targeting ADC - (<i>Besponsa</i>).
CD22 targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 100 |
| A.7 | Cluster of Differentiation 30 (CD30) -
Insights on approved CD30 targeting ADC (<i>Adcetris</i>).
CD22 targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 101 |
| A.8 | Cluster of Differentiation 19 (CD19) -
Insights on approved CD19 targeting ADC (<i>Zynlonta</i>).
CD22 targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 102 |
| A.9 | Cluster of Differentiation 33 (CD33) -
Insights on approved CD33 targeting ADC (<i>Mylotarg</i>).
CD22 targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline. | 103 |

- A.10 *Cluster of Differentiation 79b (CD79b)* - **105**
 Insights on approved CD79b targeting ADC (*Polivy*).
 CD79b targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline.
- A.11 *Hepatocyte Growth Factor Receptor (C-MET)* - **106**
 Insights on approved c-Met targeting ADC (*Emrelis*).
 c-Met targeting ADCs & Bispecific ADCs in Clinical & Preclinical Pipeline.

Cluster B □ **Promising / Advanced ADC Targets -** **108**
(Includes Phase II / III Pipeline, with broad Industry Investments)

- B.1 *B7-H3 & B7-H4*, targeting ADCs in Clinical & Preclinical Development.
- B.2 *Epidermal Growth Factor Receptor (EGFR)*, targeting ADCs in Clinical & Preclinical Development.
- B.3 *Human Epidermal Growth Factor Receptor 3 (HER3)*, targeting ADCs in Clinical & Preclinical Development.
- B.4 *Claudin18.2 & Claudin 6*, targeting ADCs in Clinical & Preclinical Development.
- B.5 *ROR 1 & ROR 2*, targeting ADCs in Clinical & Preclinical Development.
- B.6 *Prostate-Specific Membrane Antigen (PSMA)*, targeting ADCs in Clinical & Preclinical Development.

Cluster C □ **Emerging Novel ADC Targets -** **122**
(Includes Preclinical - Early Phase I ADC Molecules)

- C.1 *Programmed Death-Ligand 1 (PD-L1)* targeting ADCs in Clinical & Preclinical Development.
- C.2 *Cadherin-17, Cadherin-6 & Cadherin-1* targeting ADCs in Clinical & Preclinical Development.
- C.3 *Mucin-1 (MUC1)* targeting ADCs in Clinical & Preclinical Development.
- C.4 *CEACAM5 & CEACAM6* targeting ADCs in Clinical & Preclinical Development.
- C.5 *Trophoblast Glycoprotein (5T4)* targeting ADCs in Clinical & Preclinical Development.
- C.6 *Tyrosine-Protein Kinase-like 7 (PTK7)* targeting ADCs in Clinical & Preclinical Development.
- C.7 *Delta-like 3 (Drosophila) (DLL3)* targeting ADCs in Clinical & Preclinical Development.
- C.8 *LIV-1*, targeting ADCs in Clinical & Preclinical Development
- C.9 *NaPi2b* targeting ADCs in Clinical & Preclinical Development.
- C.10 *FGFR* targeting ADCs in Clinical & Preclinical Development
- C.11 *STING* targeting ADCs in Clinical & Preclinical Development.
- C.12 *MESOTHELIN* targeting ADCs in Clinical & Preclinical Development.

Cluster D □ *Hematologic Specific ADC Targets -*

137

- D.1 *Cluster of Differentiation 45 (CD45)* targeting ADCs in Clinical / Preclinical Development
- D.2 *Cluster of Differentiation 20 (CD20)* targeting ADCs in Clinical / Preclinical Development
- D.3 *Cluster of Differentiation 123 (CD123)* targeting ADCs in Clinical / Preclinical Development.

Cluster E □ *Low Investment / Exploratory Targets -* (Includes < 5 molecules, Low pipeline density)

140

- E.1 *Glypican-3* targeting ADCs in Clinical & Preclinical Development.
- E.2 *Guanylate Cyclase 2C (GC-C)* targeting ADCs in Clinical & Preclinical Development.
- E.3 *Cluster of Differentiation (CD56)* targeting ADCs in Clinical / Preclinical Development.
- E.4 *DLK-1*, targeting ADCs in Clinical & Preclinical Development.
- E.5 *CD73*, targeting ADCs in Clinical & Preclinical Development.

□ **Antibody Drug Conjugates (ADC) Drug Development Landscape - 2025**

Individual ADC Development Pipeline Insights

- ***Phase III & II/III Antibody Drug Conjugates in Clinical Development.*** 143
ADC | Developer/Partners | Target | Payload | Linker | DAR | Conjugation Technology | NCT Number | Key Indication. | Expected Launch.
- ***Phase II & I/II Antibody Drug Conjugates in Clinical Development.*** 147
ADC | Developer/Partners | Target | Payload | Linker | DAR | Conjugation Technology | NCT Number | Key Indication.
- ***Phase I Antibody Drug Conjugates in Clinical Development.*** 154
ADC | Developer/Partners | Target | Payload | Linker | DAR | Conjugation Technology | NCT Number | Key Indication.
- ***BiSpecific Antibody Drug Conjugates in Clinical & Preclinical Development.*** 163
ADC | Developer/Partners | Target | Payload | Linker | DAR | Conjugation Technology | NCT Number | Key Indication.
- ***ADC Like Molecules in Clinical & Preclinical Development.*** 172
Protein Drug Conjugates | Antibody Radionucleotide Conjugates | Antibody Toxin Conjugates | Antibody Oligonucleotide Conjugate | Immunostimulatory Antibody Conjugates | Antibody Degradable Conjugates | Antibody Inhibitor Conjugates | etc.

Discontinued ADCs During Clinical Development 176

□ *Last Development Phase III (6 Molecules)*

ADC | Developer | Target | Key Indication | Payload | Linker | Discontinuation Reason | Year

□ *Last Development Phase III/II & II (23 Molecules)*

ADC | Developer | Target | Key Indication | Payload | Linker | Discontinuation Reason | Year

□ *Last Development Phase I/II & I (97 Molecules)*

ADC | Developer | Target | Key Indication | Payload | Linker | Discontinuation Reason | Year

□ Antibody Drug Conjugates (ADCs) Funding, Deals & Alliance Landscape - 2025 186

Insights on Drug Development Funding & Deals in ADC

□ *ADCs Drug Development Companies - Private Funding 2025* 186

Insights on ADC Drug Developers who raised Funds through Private Financing

□ *ADCs Drug Development Companies - Private Financing 2023-2024* 187

Insights on ADC Drug Developers who raised Funds through Private Financing.

□ *Major Business Mergers & Acquisitions in Antibody Drug Conjugates Domain in Past Two Years (2025-23)* 191

Pre-build Intelligence on ADC Drug Developers Deals in 2023 & 2024

□ *Antibody Drug Conjugates Drug Development Companies - Major Business Deals & Collaborations in 2025* 194

Pre-build Intelligence on ADC Drug Developers Alliance with Non-Profits.

□ *Antibody Drug Conjugates Drug Development Companies - Major Business Deals & Collaborations in 2023-2024* 197

Pre-build Intelligence on ADC Drug Developers Alliance with Non-Profits.

Section B

□ Global ADCs Drug Developers - 2025	212
<i>Summary on Active ADC Drug Developers</i>	
□ <i>Active ADC Drug Development Companies present in United States, Europe, Asia, Canada and Australia.</i>	213
□ <i>Country-wise Distribution of ADC Drug Developers in Europe & Asia.</i>	213
Identify Countries Supporting ADC Drug Development in the Region.	
□ <i>TOP 20 ADC Drug Development Companies Worldwide</i>	214
□ Individual Profiles of Active Antibody Drug Conjugates Drug Developer Companies	215
Individual Drug Developer Profile includes:	
Company Overview	
Key Technology Platform	
Key ADC Linked Patents	
ADC centered Collaborations, Deals & Partnership.	
Funding Details	
Antibody Drug Conjugate Pipeline –Drugs name, its targets, with details of its development for various indications, NCT Number, Drug Modality.	
Management Profile –Address, Contact number, e-mail, Key Management / Decision Maker (CXOs) name and designation, with individual Linked ID and contact emails.	

Appendix A: List of Antibody Drug Conjugates Drug Development Companies..... 719

ASIA	<i>Companies Present in China</i> <i>Companies Present in India</i> <i>Companies Present in Israel</i> <i>Companies Present in Japan</i> <i>Companies Present in Singapore</i> <i>Companies Present in South Korea</i> <i>Companies Present in Taiwan</i>
EUROPE	<i>Companies Present in Belgium</i> <i>Companies Present in Check Republic</i> <i>Companies Present in Denmark</i> <i>Companies Present in Finland</i> <i>Companies Present in France</i> <i>Companies Present in Germany</i> <i>Companies Present in Italy</i> <i>Companies Present in Netherlands</i> <i>Companies Present in Norway</i> <i>Companies Present in Poland</i> <i>Companies Present in Portugal</i> <i>Companies Present in Spain</i> <i>Companies Present in Sweden</i> <i>Companies Present in Switzerland</i> <i>Companies Present in United Kingdom</i>
NORTH AMERICA	<i>Companies Present in Canada</i> <i>Companies Present in United States of America</i>
AUSTRALIA	<i>Companies Present in Australia</i>